Cardiff Oncology Inc reports results for the quarter ended in March - Earnings Summary

Cardiff Oncology

04/05/2023 22:04

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly
adjusted
loss of 25 cents​​ per share for the quarter ended in March. The
mean expectation of five analysts for the quarter was for a loss
of 23 cents per share.
    * Revenue rose 12.2% to $83.00 thousand from a year ago;
analysts
expected $55.60 thousand. 
    * Cardiff Oncology Inc's reported EPS for the quarter was a
loss
of 25 cents​.
    * The mean earnings estimate of analysts had risen by
about 13.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cardiff Oncology Inc shares had risen by 12.7% this
quarter and
gained 32.9% so far this year.
    * The company reported a quarterly loss of $11.23 million.
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
4 at 09:04 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.23          -0.25          Missed
 Dec. 31 2022      -0.23          -0.20          Beat
 Sep. 30 2022      -0.26          -0.20          Beat
 Jun. 30 2022      -0.25          -0.24          Beat